
Revolution Medicines starts phase 3 trial of zoldonrasib in pancreatic cancer
- Revolution Medicines has started treating patients in its global Phase 3 trial of zoldonrasib for pancreatic cancer.
- Shares of the company moved upward to $165.81 following the operational update.
- The study forms a core part of the firm's broader strategy to deliver targeted therapies for RAS-mutated tumors.
Revolution Medicines (NASDAQ:RVMD) began dosing patients in its global Phase 3 RASolute 305 trial for metastatic pancreatic cancer.
This late-stage evaluation follows positive earlier developments in the company's RAS-mutant oncology research programs over the past year.
The double-blind study evaluates the oral drug zoldonrasib alongside investigator-selected chemotherapy drugs against a standard placebo combination.
The company stated that primary goals are focused strictly on determining overall survival and progression-free survival metrics.
Following the announcement, Revolution Medicines' share price was up at $165.81.
The oncology specialist focuses entirely on discovering and developing targeted therapies for patients living with complex RAS-mutant cancers.
This specific global study marks the latest regulatory milestone for the business as it expands its active clinical pipeline.
More from United States
Anthropic prices IPO above range at $83, sources say
Palo Alto Networks revenue advances to $3.44 billion, up 39%
Woodward records 22% sales growth in fiscal 2026 as revenue hits $4.4B
C3is reports $1.2 million Q3 net loss as revenue rises
Cosmos Health revenue hits $53.6 million, up 17.6%
Summit launches Phase III lung cancer trial for ivonescimab